Drug costs in context: assessing drug costs in cost-of-illness analyses.
burden-of-illness
cost-of-illness
drug costs
pharmacoeconomics
Journal
Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187
Informations de publication
Date de publication:
2022
2022
Historique:
received:
09
05
2022
accepted:
13
06
2022
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
12
8
2022
Statut:
epublish
Résumé
Cost-of-illness (COI) studies attempt to measure and describe the costs associated or attributed to a specific disease, but there are several considerations for measuring and interpreting drug costs estimates. The complexity of the pharmaceutical supply chain and contractual relationships between manufacturers, wholesalers, pharmacies and payers create challenges for researchers attempting to include drug costs in COI analyses. This article aims to provide contextual information for a general audience interested in conducting or evaluating COI studies that may include drug costs and to describe key factors to consider when reviewing drug costs in the peer-reviewed literature.
Identifiants
pubmed: 35949272
doi: 10.7573/dic.2022-5-4
pii: dic-2022-5-4
pmc: PMC9333414
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright © 2022 Mattingly II TJ, Weathers S.
Déclaration de conflit d'intérêts
Disclosure and potential conflicts of interest: TJM reports consultant fees from the Arnold Foundation and PhRMA, all unrelated to this review. TJM also reports research grant support from PhRMA, the Patient-Centered Outcomes Research Institute, and the Food and Drug Administration unrelated to this review. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2022/06/dic.2022-5-4-COI.pdf
Références
J Dermatol. 2020 Jul;47(7):689-698
pubmed: 32383191
Value Health. 2018 Jun;21(6):677-684
pubmed: 29909872
Inj Prev. 2000 Sep;6(3):177-9
pubmed: 11003181
Value Health. 2010 Jan-Feb;13(1):14-7
pubmed: 19883404
Value Health. 2019 Sep;22(9):1026-1032
pubmed: 31511179
Annu Rev Public Health. 2020 Apr 2;41:499-512
pubmed: 31874070
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Pharmacoeconomics. 2001;19(2):207-13
pubmed: 11284384
Endocrinol Diabetes Metab. 2020 May 07;3(3):e00133
pubmed: 32704557
Ann Intern Med. 2018 Mar 20;168(6):436-437
pubmed: 29435565
J Med Econ. 2019 May;22(5):421-429
pubmed: 30724682
Pharmacoeconomics. 2006;24(9):869-90
pubmed: 16942122
J Gastrointest Oncol. 2021 Apr;12(2):658-668
pubmed: 34012657
Health Aff (Millwood). 2011 Aug;30(8):1529-38
pubmed: 21821570
Orphanet J Rare Dis. 2020 Jun 12;15(1):149
pubmed: 32532288
Int J Rheum Dis. 2021 May;24(5):671-680
pubmed: 33729682
Pharmacoeconomics. 2017 Feb;35(2):215-223
pubmed: 27798809
Pharmacoeconomics. 2018 Sep;36(9):1093-1099
pubmed: 29752675
Am J Public Health Nations Health. 1967 Mar;57(3):424-40
pubmed: 6066903
Health Aff (Millwood). 2019 Apr;38(4):604-612
pubmed: 30933574
Acta Med Port. 2019 Apr 30;32(4):272-278
pubmed: 31067421
Pharmacoeconomics. 2011 Aug;29(8):653-71
pubmed: 21604822
Hemodial Int. 2021 Jan;25(1):123-130
pubmed: 33145981
Q J Econ. 2019 Feb;134(1):51-107
pubmed: 32981974
Value Health. 2018 Feb;21(2):119-123
pubmed: 29477388
Ther Clin Risk Manag. 2021 Apr 21;17:345-356
pubmed: 33911870
Health Aff (Millwood). 2019 Feb;38(2):184-189
pubmed: 30715987
Health Policy Plan. 2012 May;27(3):213-21
pubmed: 21486910
Pharmacoeconomics. 2016 Jan;34(1):43-58
pubmed: 26385101
PLoS One. 2019 Oct 10;14(10):e0223316
pubmed: 31600241
Clinicoecon Outcomes Res. 2020 Mar 06;12:133-140
pubmed: 32184636
Inj Prev. 2000 Sep;6(3):175-6
pubmed: 11003180
Pharmacoeconomics. 2017 May;35(5):493-500
pubmed: 28210864